| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
KH-176 (Sonlicromanol) is a novel, potent small molecule ROS-redox modulator with the potential for the treatment of mitochondrial diseases. KH-176 targets the reactive oxygen species which are important in the pathogenesis of disorders of mitochondrial oxidative phosphorylation. KH-176 effectively reduces increased cellular ROS levels and protects OXPHOS deficient primary cells against redox perturbation by targeting the Thioredoxin/Peroxiredoxin system.
| ln Vivo |
The pharmacotherapy of mitochondrial illnesses linked with CI deficiency may benefit from the use of sonlicromanol (KH176, 10 mg/kg, intraperitoneally, twice daily), as long as it is used independently and without additive effects [3].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Ndufs4−/− mice [3].
Doses: 10 mg/kg. Route of Administration: intraperitoneal (ip) injection twice (two times) daily. Experimental Results: Ndufs4−/− mice experienced increased lifespan, similar to KH176 and clofibrate monotherapy. |
| References |
[1]. X Jiang, et al. Mechanism of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-1-mediated PGE 2 biosynthesis by sonlicromanol's metabolite KH176m. Sci Rep. 2021 Jan 13;11(1):880.
[2]. Zikai Feng, et al. Comparative In Vitro Toxicology of Novel Cytoprotective Short-Chain Naphthoquinones. Pharmaceuticals (Basel). 2020 Aug 7;13(8):184. [3]. Sanne J C M Frambach, et al. Effects of clofibrate and KH176 on life span and motor function in mitochondrial complex I-deficient mice. Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165727. |
| Additional Infomation |
Sonlicromanol is being studied in the clinical trial NCT04165239 (KHENERGYZE study).
|
| Molecular Formula |
C19H28N2O3
|
|---|---|
| Molecular Weight |
332.437225341797
|
| Exact Mass |
332.209
|
| CAS # |
1541170-75-5
|
| Related CAS # |
Sonlicromanol hydrochloride;2162149-24-6
|
| PubChem CID |
72710875
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
570.8±50.0 °C at 760 mmHg
|
| Flash Point |
299.0±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
2.39
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
472
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=C(C2=C(CC[C@@](O2)(C)C(=O)N[C@@H]3CCCNC3)C(=C1O)C)C
|
| InChi Key |
LZYWLEPSQNXESC-KUHUBIRLSA-N
|
| InChi Code |
InChI=1S/C19H28N2O3/c1-11-12(2)17-15(13(3)16(11)22)7-8-19(4,24-17)18(23)21-14-6-5-9-20-10-14/h14,20,22H,5-10H2,1-4H3,(H,21,23)/t14-,19+/m1/s1
|
| Chemical Name |
(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chromane-2-carboxamide
|
| Synonyms |
Sonlicromanol KH-176 KH 176 KH176
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~25 mg/mL (~75.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0081 mL | 15.0403 mL | 30.0806 mL | |
| 5 mM | 0.6016 mL | 3.0081 mL | 6.0161 mL | |
| 10 mM | 0.3008 mL | 1.5040 mL | 3.0081 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
